Small Is Better: Why the Gulf’s Diagnostics Sovereignty Moment Demands the Right Architecture
A few years ago, as I was exploring relocating my company to a Gulf country, I sat with the innovation lead of a regional development programme. He was visibly excited as he described how a major diagnostics multinational had committed to building a presence in his country: investment, jobs, a regional hub. The whole language of the partnership was ambitious. As I asked what was actually being built, I realised that the org chart had a handful of desk-based roles supporting commercial operations and ESG compliance, shared services, but no manufacturing nor R&D. Grandiose announcements for distribution support with better branding. I know that model from Europe too well, and in my very peripheral home country in particular, where the major international pharmaceutical companies maintain elegant offices and well-dressed teams focused exclusively on driving adoption and sales. No sovereignty emerges from their presence.
That gap between what gets announced and what gets built is what this article is about, and the post-war reconstruction moment makes it urgent.
The post-war conversation on resilience and sovereignty
Since the Hormuz crisis, a serious and substantive discussion has been unfolding about what the Gulf needs to build differently. The Middle East Council on Global Affairs has been one of the most consistent analytical voices in that conversation. Writing in March, Frédéric Schneider identified the structural stakes plainly: the Gulf’s Vision strategies rest on a premise of stability that the conflict put under severe strain, and the explicit response must include onshoring critical industries. Nayef Al-Nabet went further, arguing that a sustained Hormuz closure would disrupt access to imported materials, components, and equipment throughout the Gulf, undermining not only short-term resilience but the foreign capital attraction on which diversification depends. By late March, Yousuf Hamad Al Balushi was framing the imperative in terms of intellectual sovereignty: after fifty years of imported models and external prescriptions, the Gulf now has the capacity to develop its own solutions, and the next decade will be defined by how confidently it does so.
I agree with all of this, obviously. What I want to add here is a specific and largely overlooked dimension: diagnostics manufacturing. Not pharmaceuticals, which get attention in localisation discussions, nor the large medical devices, which get some. Specifically diagnostic reagents, the consumables that make every clinical test run, from a basic blood count to a molecular oncology panel, the reagents that disappear into laboratory stockrooms, and do their work invisibly until they run out. They move through the same maritime corridors that were disrupted, they are subject to the same supply shocks, and they are equally critical. But no GCC country produces them nor has a clear strategy to do so.
The urgency of building such supply and value chains is now obvious. The question, and this is where the post-war reconstruction moment becomes a trap as much as an opportunity, is what to build first.
The wrong instruments
When ministries start thinking about localising health manufacturing, two models surface immediately. The first is a national factory: state-owned, heavily invested, producing for domestic consumption under a captive procurement mandate. The second is a large multinational anchor: attracted by incentive packages, offering a recognisable brand and the promise of technology transfer.
I have been occasionally asked to help identify companies that could expand health manufacturing capacity in the Gulf. The mandates are always for pharma, and always spec’d for scale: maximum output, large footprint, single-site presence. Scale logic has its place: a pilot plant producing fifty thousand test kits a year contributes nothing to the resilience of a health system serving millions: volume matters.
But there is a version of scale that creates a new dependency rather than resolving an old one. A factory that becomes the sole regional producer of a critical input, whether metformin or COVID test, has simply relocated the vulnerability to a domestic address. When that factory has a quality failure, a production disruption, or a shift in its parent company’s priorities, the system fails just as completely as it did when the supply ran through Hormuz. The address has changed but the structural problem has not, as the 2021 mass recalls issued by the UAE’s sole phamaceutical manufacturer illustrate so well.
In diagnostics, this is compounded by something sector-specific: the field moves fast. Platforms evolve as fast as technology and specifically its AI powering improves. Then new pathogens demand new products on short timelines, or the new guidelines require another mutation added to the lung cancer mutational panel or the PDL1 antibody that was all the craze to guide immunotherapy has been superseded by a better, multispecific, ELISA test. A large facility optimised for one assay family is not a resilience asset in that environment, it is a fossilized investment waiting for the market to move past it. The flexibility that diagnostics sovereignty requires is structurally incompatible with the large-organisation model.
I have seen this dynamic from the inside. As part of an innovation accelerator, I watched partnerships with large health companies, partnerships that looked genuinely promising, collapse the moment the internal champion was promoted. I learnt that when dealing with large corporations, ever so frequently the deal you are negotiating is not with the company, but with the person seeking his/her own promotion only. When that person moved, institutional memory moved with them, and what remained was a counterpart who had inherited a file, but not a commitment. I have also spent months in proposal processes with large service companies for small-batch manufacturing or focused analytical work, only to receive responses priced for a different kind of client entirely. I am not claiming the proposals were in any way dishonest, but the time of reaction and the budget envelope reflect simply an organisation built for scale, applied to a problem that required agility. Large companies are not bad partners by disposition, but they are structurally misaligned with what early-stage ecosystem building requires.
The architecture that actually works
Al Balushi notes that Bahrain and Oman are already designing SME initiatives rooted in local entrepreneurial culture rather than imported from OECD templates. The same logic applies to diagnostics manufacturing, but the companies do not need to be local startups. They already exist.
Europe has hundreds of 20 to 80 person specialist manufacturers producing enzymes, oligonucleotides, master mixes, immunoassay components, plasticware, and fill-finish services under ISO 13485, already operating under the world’s most demanding regulatory frameworks, already shaped by the compliance infrastructure that diagnostics manufacturing requires. They are not regulatory novices. They are battle-hardened companies structurally underserved by a European market that has little room for them to grow and desperate – even if they don’t know it yet – for expansion beyond the safe and stagnated European shores. The Gulf, post-Hormuz, is the market that needs exactly what they produce. Should several relocate their production capability to the Gulf, they would very quickly build the resilient ecosystem that the Gulf requires. The investment that the sovereign funds so like to announce on a single major partnership would bring 10 or 20 such companies and enable them to establish and run at speeds that only owner-driven SMEs are capable of.
In the architecture I propose, no single company holds a captive mandate. Hospitals and laboratories choose on quality and performance. The state acts as co-investor, not monopolist, deploying sovereign capital conditionally against measurable supply chain impact outcomes rather than against ownership stakes or factory mandates. GCC sovereign wealth funds, which collectively manage nearly five trillion dollars and are already reorienting toward regional resilience strategies, are the natural vehicle for this. Large corporations belong in this picture too, but at the end of the sequence: when the market is deep enough to attract them on merit, when regulatory pathways are functional, and when a domestic ecosystem exists that their presence amplifies rather than replaces.
The cost of choosing wrong
The BGI trajectory in Saudi Arabia illustrates what happens when urgency drives instrument choice, and how emergency entry compounds into structural dependency. During COVID-19, BGI and NUPCO signed an agreement to establish six Huo-Yan laboratories across the Kingdom, processing over 18 million PCR tests and accounting for nearly half of Saudi Arabia’s total testing volume. That emergency relationship became the foundation for Genalive, a joint venture with Tibbiyah Holding launched in 2023: a 4,000 square metre clinical genomics facility in Riyadh, subsequently awarded a three-year NUPCO contract in 2025 covering more than 930,000 genetic testing services across 83 public hospitals. BGI describes itself as a long-term partner and enabler of Vision 2030. What Saudi Arabia has in practice is a Chinese genomics company with a sovereign procurement contract, a healthcare data centre, and a joint venture structure that is not easily exited. Critically, Genalive is a service laboratory, not a manufacturer: the sequencing platforms are BGI/MGI equipment, the reagents are imported from China. What was built in Riyadh is a Chinese-supplied operation under a Saudi brand. The dependency on Chinese supply for instruments and reagents is structurally unchanged. Only the address of the service layer moved. I have written previously about this pattern of Gulf partnerships that mistake localisation for sovereignty – the BGI case is its clearest expression to date.
Schneider’s March analysis concluded that the Gulf’s economic response to the conflict must include onshoring critical industries and building redundant, war-proof supply networks. Al-Nabet identified imported materials and components as the systemic vulnerability that a Hormuz closure exposes most brutally. Al Balushi argued that the Gulf must now trust its own capacity to design solutions rather than import them.
Diagnostics manufacturing is where all three arguments converge, and where the reconstruction moment is most likely to produce the wrong answer if the sequencing question is not asked explicitly. A national factory can be inaugurated in one political cycle. A multinational deal can be signed at one summit. An ecosystem of independent specialist manufacturers covering the full diagnostics value chain is harder to narrate and less appealing to photograph at a ribbon-cutting. But I am convinced it is the only architecture that holds when the next shock arrives.
This article draws on research developed in The Import Condition: Diagnostics, Sovereignty, and the Gulf’s Industrial Moment, forthcoming December 2026.
References: Frédéric Schneider, “The Costs of the Iran Conflict for the Gulf,” ME Council, March 2026 | Nayef Al-Nabet, “The Gulf Stability Model is Under Pressure,” ME Council, March 2026 | Yousuf Hamad Al Balushi, “Why the Gulf Must Build Its Own Economic Playbook,” ME Council, March 2026 | ME Council, “Gulf Sovereign Wealth Funds and the Cost of Crisis Resilience,” May 2026 | World Bank, MENAAP Economic Update, April 2026 | BGI Genomics, “BGI Genomics Taps AI to Power Healthcare Transformation in Saudi Vision,” September 2025 | Berlemann, Jahn & Lehmann, “Is the German Mittelstand More Resistant to Crises?,” Small Business Economics, 2022 | UNIDO, SME Cluster and Network Development, 1999 and 2024